` SCYX (SCYNEXIS Inc) vs S&P 500 Comparison - Alpha Spread

SCYX
vs
S&P 500

Over the past 12 months, SCYX has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's 12% growth.

Stocks Performance
SCYX vs S&P 500

Loading

Performance Gap
SCYX vs S&P 500

Loading
SCYX
S&P 500
Difference

Performance By Year
SCYX vs S&P 500

Loading
SCYX
S&P 500
Add Stock

Competitors Performance
SCYNEXIS Inc vs Peers

S&P 500
SCYX
LLY
JNJ
NOVO B
ROG
Add Stock

SCYNEXIS Inc
Glance View

Market Cap
30m USD
Industry
Pharmaceuticals

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 56 full-time employees. The company went IPO on 2014-05-02. The firm is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. The company has received the approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC). The company is also continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients.

SCYX Intrinsic Value
Not Available
Back to Top